GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTP) » Definitions » 12-1 Month Momentum %

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) 12-1 Month Momentum % : N/A% (As of May. 16, 2024)


View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-16), 60 Degrees Pharmaceuticals's 12-1 Month Momentum % is N/A%.

The industry rank for 60 Degrees Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:

SXTP's 12-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -22.72
* Ranked among companies with meaningful 12-1 Month Momentum % only.

Competitive Comparison of 60 Degrees Pharmaceuticals's 12-1 Month Momentum %

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


60 Degrees Pharmaceuticals's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's 12-1 Month Momentum % falls into.



60 Degrees Pharmaceuticals  (NAS:SXTP) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


60 Degrees Pharmaceuticals  (NAS:SXTP) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


60 Degrees Pharmaceuticals 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases through Arakoda and Celgosivir.
Executives
Charles W Allen director 1881 N. NASH STREET, UNIT 701, ARLINGTON VA 22209
Kentucky Technology Inc. 10 percent owner 824 BULL LEA RUN, SUITE 2100, LEXINGTON KY 40511
Cheryl Xu director 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Paul Field director 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Tyrone Miller officer: Chief Financial Officer 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Geoffrey S Dow director, 10 percent owner, officer: CEO and President 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Florida State University Research Foundation Inc. 10 percent owner 200 LEVY AVENUE, BUILDING A, SUITE 351, TALLAHASSEE FL 32310
Bryan Lee Smith officer: Chief Medical Officer 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Stephen Toovey director 1025 CONNECTICUT AVENUE NW, SUITE 100, WASHINGTON DC 20036